Inhibition of cyclooxygenase-2: An approach to preventing cancer of the upper aerodigestive tract

Andrew J. Dannenberg; Nasser K. Altorki; Jay O. Boyle; Derrick T. Lin; Kotha Subbaramaiah

doi:10.1111/j.1749-6632.2001.tb02731.x

Inhibition of cyclooxygenase-2: An approach to preventing cancer of the upper aerodigestive tract

Andrew J. Dannenberg, Nasser K. Altorki, Jay O. Boyle, Derrick T. Lin, Kotha Subbaramaiah

Research output: Contribution to journal › Article › peer-review

56 Scopus citations

Abstract

Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2), an inducible form of COX, represents a potential pharmacologic target to prevent cancer. Key data suggesting a causal relationship between increased COX-2 activity and carcinogenesis and possible mechanisms of action of COX-2 in this context will be discussed. The possibility that COX-2 represents a pharmacological target for preventing upper aerodigestive cancers (head and neck, lung) will be emphasized. Importantly, clinical trials have been initiated to assess the chemopreventive properties of selective COX-2 inhibitors.

Original language	English (US)
Pages (from-to)	109-115
Number of pages	7
Journal	Annals of the New York Academy of Sciences
Volume	952
DOIs	https://doi.org/10.1111/j.1749-6632.2001.tb02731.x
State	Published - 2001

Keywords

Aerodigestive
Chemoprevention
Cyclooxygenase-2
Nonsteroidal anti-inflammatory drugs
Prostaglandins

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1111/j.1749-6632.2001.tb02731.x

Cite this

@article{7cfd2cb55824472e9a14118b2d7aa95c,

title = "Inhibition of cyclooxygenase-2: An approach to preventing cancer of the upper aerodigestive tract",

abstract = "Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2), an inducible form of COX, represents a potential pharmacologic target to prevent cancer. Key data suggesting a causal relationship between increased COX-2 activity and carcinogenesis and possible mechanisms of action of COX-2 in this context will be discussed. The possibility that COX-2 represents a pharmacological target for preventing upper aerodigestive cancers (head and neck, lung) will be emphasized. Importantly, clinical trials have been initiated to assess the chemopreventive properties of selective COX-2 inhibitors.",

keywords = "Aerodigestive, Chemoprevention, Cyclooxygenase-2, Nonsteroidal anti-inflammatory drugs, Prostaglandins",

author = "Dannenberg, {Andrew J.} and Altorki, {Nasser K.} and Boyle, {Jay O.} and Lin, {Derrick T.} and Kotha Subbaramaiah",

year = "2001",

doi = "10.1111/j.1749-6632.2001.tb02731.x",

language = "English (US)",

volume = "952",

pages = "109--115",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley",

}

TY - JOUR

T1 - Inhibition of cyclooxygenase-2

T2 - An approach to preventing cancer of the upper aerodigestive tract

AU - Dannenberg, Andrew J.

AU - Altorki, Nasser K.

AU - Boyle, Jay O.

AU - Lin, Derrick T.

AU - Subbaramaiah, Kotha

PY - 2001

Y1 - 2001

N2 - Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2), an inducible form of COX, represents a potential pharmacologic target to prevent cancer. Key data suggesting a causal relationship between increased COX-2 activity and carcinogenesis and possible mechanisms of action of COX-2 in this context will be discussed. The possibility that COX-2 represents a pharmacological target for preventing upper aerodigestive cancers (head and neck, lung) will be emphasized. Importantly, clinical trials have been initiated to assess the chemopreventive properties of selective COX-2 inhibitors.

AB - Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2), an inducible form of COX, represents a potential pharmacologic target to prevent cancer. Key data suggesting a causal relationship between increased COX-2 activity and carcinogenesis and possible mechanisms of action of COX-2 in this context will be discussed. The possibility that COX-2 represents a pharmacological target for preventing upper aerodigestive cancers (head and neck, lung) will be emphasized. Importantly, clinical trials have been initiated to assess the chemopreventive properties of selective COX-2 inhibitors.

KW - Aerodigestive

KW - Chemoprevention

KW - Cyclooxygenase-2

KW - Nonsteroidal anti-inflammatory drugs

KW - Prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=0035683884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035683884&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2001.tb02731.x

DO - 10.1111/j.1749-6632.2001.tb02731.x

M3 - Article

C2 - 11795429

AN - SCOPUS:0035683884

SN - 0077-8923

VL - 952

SP - 109

EP - 115

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

ER -

Inhibition of cyclooxygenase-2: An approach to preventing cancer of the upper aerodigestive tract

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this